샘플 요청 목록

 카트 문의
시장보고서
상품코드
1742781

세계의 구강인두 칸디다증 시장

Oropharyngeal Candidiasis
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 462 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 구강인두 칸디다증 시장은 2030년까지 4억 8,920만 달러에 이를 전망

2024년에 4억 2,460만 달러로 추정된 구강인두 칸디다증 세계 시장은 2030년에는 4억 8,920만 달러에 이르고, 분석 기간 2024-2030년 CAGR은 2.4%를 보일 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 위막성은 CAGR 2.0%를 나타내고, 분석 기간 종료시에는 2억 9,730만 달러에 이를 것으로 예측됩니다. 붉은 반점성 부문의 성장률은 분석 기간중 CAGR 2.9%로 추정됩니다.

미국 시장은 1억 1,570만 달러로 추정, 중국은 CAGR 4.5%를 보일 것으로 예측

미국의 구강인두 칸디다증 시장은 2024년에 1억 1,570만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년간 CAGR 4.5%로 2030년에는 예측 시장 규모 9,310만 달러에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 0.9%와 1.8%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 1.3%를 보일 전망입니다.

세계의 구강인두 칸디다증 시장 - 주요 동향과 촉진요인 정리

구강인두 칸디다증이 더 이상 사소한 기회감염이 아닌 이유는 무엇인가?

일반적으로 구강인두 칸디다증(OPC)은 주로 칸디다 알비칸스(Candida albicans), 최근에는 칸디다 그라브라타(Candida gravlata), 칸디다 크루세이(Candida crucei)와 같은 비알비칸스 종에 의해 유발되는 점막의 진균 감염으로, 흔히 경미한 질환으로 치부되기 쉽습니다. 현재는 특히 HIV/AIDS, 혈액악성종양, 장기이식, 화학요법 및 코르티코스테로이드 요법을 받는 환자에서 전신 면역억제증의 중요한 지표로 간주되고 있습니다. 면역억제 요법과 흡입용 코르티코스테로이드의 사용이 증가함에 따라 위험군이 확대되고 OPC 관리에 대한 임상적 관심이 높아지고 있습니다.

또한 항진균제 내성균, 특히 플루코나졸 노출자의 출현은 치료 프로토콜을 복잡하게 만들고 있으며, OPC는 재발성일 뿐만 아니라 취약한 환자에서 전신 칸디다증과 관련이 있습니다. 이 때문에 강력한 항진균제 관리, 진단 방법의 개선, 내성에 강한 새로운 제제의 필요성이 대두되고 있습니다. 또한, 고령자, 의치 착용자, 당뇨병 환자의 OPC 부담은 전 세계 평균 수명 증가와 도시 식생활의 변화로 인해 증가하고 있습니다.

보다 효과적인 관리를 위해 진단법과 국소 치료법은 어떻게 진화하고 있는가?

기존에는 OPC의 진단은 임상 검사 및 증상 소견에 의존했지만, 종의 다양성과 내성이 증가함에 따라 보다 정확한 진단 워크플로우가 필요하며, KOH 염색을 이용한 현미경 검사, 그람 염색, 배양 기반 분석 등이 여전히 널리 사용되고 있습니다. 그러나 정확한 병원체 감별과 항진균제 감수성 프로파일링을 위해 PCR을 통한 균종 동정, MALDI-TOF 질량분석, 차세대 시퀀싱(NGS) 등의 분자진단 도구가 주목받고 있습니다.

치료적으로는 나이스타틴, 클로트리마졸, 미코나졸 등의 외용 항진균제가 합병증을 동반하지 않는 OPC의 1차 선택 약제로 사용되고 있습니다. 그러나 중등도 이상의 중증 및 재발 사례에서는 플루코나졸, 이트라코나졸, 포사코나졸 등의 아졸계 전신약물이 처방되는 경우가 많습니다. 난치성 감염이나 내성균이 관여하는 감염에는 에키노칸딘계 항진균제나 암포테리신 B가 고려됩니다. 레자팡진, 이브 렉사 팡가프와 같은 신규 항진균제는 더 넓은 스펙트럼을 가지고 있고 내성률이 낮아 개발 중이거나 임상 사용 초기 단계에 있습니다.

항진균제 내성과 재발성 감염이 기술 혁신을 촉진하는 이유는 무엇일까?

항진균제 내성 문제는 암 환자 및 이식 환자에서 아졸계 항진균제의 광범위한 사용 및 장기 예방적 투여와 관련이 있으며, OPC 연구를 형성하는 큰 힘이 되고 있습니다. 칸디다 오리스와 특정 비알비칸스 균종은 다제 내성을 나타내므로 감염 제어 프로토콜을 강화해야 합니다. 따라서 살균성 대체 약물, 더 나은 전달 수단(점착성 겔, 로젠지, 서방형 정제 등) 및 전신 노출을 최소화하면서 효능을 높일 수 있는 병용 요법이 절실히 요구되고 있습니다.

특히 면역결핍 집단에서 재발성 OPC는 억제 요법과 장기 유지 전략에 대한 수요를 주도하고 있습니다. 프로바이오틱스 요법, 숙주 지향성 면역 조절제, CRISPR 기반 항진균 기술 등이 조기에 연구되고 있습니다. 이와 병행하여 고위험군에게 예방적 또는 보조적 방어를 제공하기 위해 칸디다 항원을 표적으로 하는 백신 연구가 진행 중입니다.

구강인두 칸디다증 솔루션에 대한 세계 시장 수요의 원동력은 무엇인가?

구강인두 칸디다증 시장의 성장 원동력은 전 세계 면역 억제 부담 증가, 고령화, 면역 조절제의 보급, 항진균제 내성 증가 등입니다. 특히, 자원이 부족한 환경에서 HIV 양성자 및 종양 환자의 OPC 유병률 증가는 진단 지연으로 인해 전신 합병증을 유발할 수 있는 주요 촉진요인으로 작용하고 있습니다.

의약품의 기술 혁신, 진균증 관리를 위한 공공 의료비 지원, 외래 치료 모델의 부상도 시장 확대를 뒷받침하고 있습니다. 또한, 치과 의료에 대한 인식이 높아지고 정기적인 구강관리가 보편화되면서 특히 고위험군인 노인과 당뇨병 환자의 조기 발견 및 개입률이 향상되고 있습니다.

항진균제 내성, 재발성 감염, 동반된 위험 요인이 OPC의 임상적 발자국을 계속 확대함에 따라 정확한 진단, 안전하고 효과적인 치료제, 예방적 치료 시장은 지속적으로 성장할 것입니다. 앞으로의 발전은 병원체 특이적 치료와 숙주 지향적 면역학적 전략을 결합한 통합적 관리 접근법에 달려있습니다.

부문

유형(위막성, 붉은 반점성, 과형성), 치료법(항진균제, 면역 조절제), 투여 경로(경구, 국소, 기타 투여 경로), 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 예(총 36개사)

  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Biocon Limited
  • Bristol Laboratories
  • Cidara Therapeutics Inc.
  • Cipla Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • GlaxoSmithKline plc(GSK)
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Novabiotics Limited
  • NovaDigm Therapeutics
  • Pfizer Inc.
  • SCYNEXIS, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.18

Global Oropharyngeal Candidiasis Market to Reach US$489.2 Million by 2030

The global market for Oropharyngeal Candidiasis estimated at US$424.6 Million in the year 2024, is expected to reach US$489.2 Million by 2030, growing at a CAGR of 2.4% over the analysis period 2024-2030. Pseudomembranous, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$297.3 Million by the end of the analysis period. Growth in the Erythematous segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$115.7 Million While China is Forecast to Grow at 4.5% CAGR

The Oropharyngeal Candidiasis market in the U.S. is estimated at US$115.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$93.1 Million by the year 2030 trailing a CAGR of 4.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

Global Oropharyngeal Candidiasis Market - Key Trends & Drivers Summarized

Why Is Oropharyngeal Candidiasis No Longer Just a Minor Opportunistic Infection?

Oropharyngeal candidiasis (OPC), commonly known as oral thrush, is a fungal infection of the mucous membranes caused primarily by Candida albicans, and increasingly by non-albicans species such as Candida glabrata and Candida krusei. While often dismissed as a minor condition, OPC is now viewed as a critical indicator of systemic immunosuppression, particularly in patients with HIV/AIDS, hematologic malignancies, organ transplants, or those undergoing chemotherapy or corticosteroid therapy. The increasing use of immunosuppressive regimens and inhaled corticosteroids is broadening the at-risk population and driving higher clinical attention to OPC management.

Moreover, the emergence of antifungal resistance-especially among fluconazole-exposed individuals-is complicating treatment protocols. OPC is not only recurrent in nature but also linked to systemic candidiasis in vulnerable patients. This is prompting the need for robust antifungal stewardship, improved diagnostics, and newer, resistance-proof formulations. In addition, the burden of OPC among the elderly, denture wearers, and diabetic populations is growing due to rising global life expectancy and urban dietary transitions.

How Are Diagnostics and Localized Therapeutics Evolving for More Effective Management?

Conventional diagnosis of OPC relies on clinical inspection and symptomatic presentation, but rising species diversity and resistance necessitate more precise diagnostic workflows. Microscopy with KOH staining, Gram staining, and culture-based assays remain widely used. However, molecular diagnostic tools, such as PCR-based species identification, MALDI-TOF mass spectrometry, and next-generation sequencing (NGS), are gaining prominence for accurate pathogen differentiation and antifungal susceptibility profiling.

Therapeutically, topical antifungals such as nystatin, clotrimazole, and miconazole remain first-line agents for uncomplicated OPC. However, systemic azoles like fluconazole, itraconazole, and posaconazole are increasingly being prescribed in moderate to severe or recurrent cases. For refractory infections or those involving resistant species, echinocandins and amphotericin B are considered. Novel antifungals such as rezafungin and ibrexafungerp, which offer broader spectrum and lower resistance rates, are in development or early-stage clinical use.

Why Are Antifungal Resistance and Recurrent Infections Catalyzing Innovation?

The global challenge of antifungal resistance-linked to widespread azole use and prolonged prophylaxis in cancer and transplant patients-is a major force shaping OPC research. Candida auris and certain non-albicans species exhibit multidrug resistance and require heightened infection control protocols. This has created a pressing need for fungicidal alternatives, better delivery vehicles (e.g., mucoadhesive gels, lozenges, and slow-release tablets), and combination therapies that enhance efficacy while minimizing systemic exposure.

Recurrent OPC, especially in immunocompromised populations, is driving the demand for suppressive therapies and long-term maintenance strategies. Probiotic therapy, host-directed immunomodulators, and CRISPR-based antifungal technologies are under early exploration. In parallel, vaccine research targeting candidal antigens is underway to offer prophylactic or adjunctive protection in high-risk groups.

What’s Fueling the Global Market Demand for Oropharyngeal Candidiasis Solutions?

The growth in the oropharyngeal candidiasis market is driven by increasing global immunosuppression burden, aging populations, widespread use of immunomodulators, and rising antifungal resistance. A key driver is the growing prevalence of OPC among HIV-positive individuals and oncology patients, especially in resource-limited settings where delayed diagnosis can lead to systemic complications.

Pharmaceutical innovation, public health funding for mycosis management, and the rise of outpatient treatment models are also supporting market expansion. Additionally, the growing penetration of dental health awareness and regular oral care regimens is enhancing early identification and intervention rates, particularly in high-risk geriatric and diabetic populations.

As antifungal resistance, recurrent infections, and comorbid risk factors continue to expand the clinical footprint of OPC, the market for accurate diagnostics, safe and effective therapeutics, and preventive care will see sustained growth. Future advances will hinge on integrated management approaches combining pathogen-specific treatment with host-directed immunological strategies.

SCOPE OF STUDY:

The report analyzes the Oropharyngeal Candidiasis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Pseudomembranous, Erythematous, Hyperplastic); Treatment (Anti-Fungal, Immune-Modulators); Administration Route (Oral, Topical, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Biocon Limited
  • Bristol Laboratories
  • Cidara Therapeutics Inc.
  • Cipla Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • GlaxoSmithKline plc (GSK)
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Novabiotics Limited
  • NovaDigm Therapeutics
  • Pfizer Inc.
  • SCYNEXIS, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Oropharyngeal Candidiasis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Immunocompromised Conditions Drives Demand for Oropharyngeal Candidiasis Treatments
    • Expansion of Cancer Chemotherapy and Immunosuppressive Therapies Throws the Spotlight on Opportunistic Fungal Infections
    • Growth in HIV and Organ Transplant Patient Populations Spurs Need for Prophylactic and Curative Antifungals
    • OEM Innovation in Muco-Adhesive and Extended-Release Formulations Enhances Drug Retention and Efficacy
    • Increase in Resistance to Azoles and Polyenes Strengthens Business Case for Novel Antifungal Agents
    • OEM Development of Topical and Localized Drug Delivery Systems Reduces Systemic Side Effects and Improves Adherence
    • Regulatory Approvals of New-Generation Triazoles Expand Therapeutic Options in Refractory Candidiasis Cases
    • Surge in Geriatric and ICU Admissions Globally Drives Clinical Vigilance for Oral Fungal Infections
    • OEM Focus on Patient-Centric Formulations Like Lozenges and Mouthwashes Improves Accessibility in Pediatric and Geriatric Settings
    • Expansion of Oral Microbiome Research Supports Probiotic and Adjunctive Therapeutic Strategies
    • OEM Emphasis on Point-of-Care Testing and Rapid Fungal Diagnostics Enhances Treatment Timeliness
    • Increased Awareness in Oncology and Hematology Units Supports Early Candidiasis Screening Protocols
    • Growth in Telemedicine and Virtual Prescriptions Accelerates Access to Oral Antifungal Therapies
    • OEM Collaboration With Mycology Research Networks Drives Understanding of Pathogenesis and Drug Resistance
    • Focus on Antifungal Stewardship in Hospital Settings Supports Rational Prescribing and Cost Management
    • Rise in Denture Use and Oral Devices in Elderly Populations Expands Risk Profiles for Oropharyngeal Candidiasis
    • OEM Entry Into Generic and Biosimilar Formulations Enhances Price Competitiveness in Chronic Care Settings
    • Integration of Candidiasis Management in Multimorbidity Care Pathways Improves Patient Outcomes
    • Expansion of Antifungal Clinical Trials and Compassionate Use Programs Supports Innovation in Untreated Patient Segments
    • Challenges in Medication Compliance Among Immunocompromised Patients Propel Demand for Long-Acting Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oropharyngeal Candidiasis Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oropharyngeal Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Oropharyngeal Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pseudomembranous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pseudomembranous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Pseudomembranous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Erythematous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Erythematous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Erythematous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hyperplastic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hyperplastic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hyperplastic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Anti-Fungal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Anti-Fungal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Anti-Fungal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Immune-Modulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Immune-Modulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Immune-Modulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • JAPAN
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • CHINA
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • EUROPE
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Oropharyngeal Candidiasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Oropharyngeal Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • FRANCE
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 101: France Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • GERMANY
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 137: UK Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 149: Spain Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Spain Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Spain 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Spain 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 161: Russia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Russia Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Russia 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Russia 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Europe Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Europe 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Europe 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 186: Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 200: Australia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Australia Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Australia 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Australia 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • INDIA
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 212: India Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: India Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: India 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 215: India Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: India 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 218: India Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 224: South Korea Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: South Korea Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: South Korea 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: South Korea 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 248: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 249: Latin America Historic Review for Oropharyngeal Candidiasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 263: Argentina Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Argentina Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Argentina 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Argentina 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 275: Brazil Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Brazil Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Brazil 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Brazil 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 287: Mexico Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Mexico Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Mexico 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Mexico 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Latin America Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 311: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 312: Middle East Historic Review for Oropharyngeal Candidiasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 326: Iran Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Iran Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Iran 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Iran 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 338: Israel Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Israel Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 340: Israel 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 343: Israel 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Saudi Arabia Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 352: Saudi Arabia 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 355: Saudi Arabia 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 362: UAE Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: UAE Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 364: UAE 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 367: UAE 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Middle East Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
  • AFRICA
    • Oropharyngeal Candidiasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 386: Africa Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Africa Historic Review for Oropharyngeal Candidiasis by Type - Pseudomembranous, Erythematous and Hyperplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 388: Africa 15-Year Perspective for Oropharyngeal Candidiasis by Type - Percentage Breakdown of Value Sales for Pseudomembranous, Erythematous and Hyperplastic for the Years 2015, 2025 & 2030
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Oropharyngeal Candidiasis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 391: Africa 15-Year Perspective for Oropharyngeal Candidiasis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Oropharyngeal Candidiasis by Treatment - Anti-Fungal and Immune-Modulators Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Oropharyngeal Candidiasis by Treatment - Percentage Breakdown of Value Sales for Anti-Fungal and Immune-Modulators for the Years 2015, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Oropharyngeal Candidiasis by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Oropharyngeal Candidiasis by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제